Presentation is loading. Please wait.

Presentation is loading. Please wait.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release.

Published byMyron Newton Modified over 9 years ago

Similar presentations

Presentation on theme: "Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release."— Presentation transcript:

1 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release Tablets and Morphine Extended- Release Products Richard Abate, RPh, MS Safety Evaluator Division of Medication Error Prevention and Analysis Office of Surveillance and Epidemiology Richard Abate, RPh, MS Safety Evaluator Division of Medication Error Prevention and Analysis Office of Surveillance and Epidemiology

2 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 2 OverviewOverview AERS search Methods of manipulation –Oxycodone extended-release tablets –Morphine extended-release products Summary AERS search Methods of manipulation –Oxycodone extended-release tablets –Morphine extended-release products Summary

3 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 3 Voluntary, “spontaneous” reporting Facilitated by the FDA MedWatch Program Reports are stored and retrieved via Adverse Event Reporting System (AERS) database Voluntary, “spontaneous” reporting Facilitated by the FDA MedWatch Program Reports are stored and retrieved via Adverse Event Reporting System (AERS) database Adverse Event Reporting System : Spontaneous Adverse Event Reporting

4 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 4 AERS Strengths Includes all U.S. marketed products Detection of events not seen in clinical trials Especially good for events with rare background rate, short latency Includes all U.S. marketed products Detection of events not seen in clinical trials Especially good for events with rare background rate, short latency

5 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 5 AERS Limitations Extensive underreporting Quality of reports is variable Reporting biases Actual numerator & denominator not known Causality of drug-event association often in question Extensive underreporting Quality of reports is variable Reporting biases Actual numerator & denominator not known Causality of drug-event association often in question

6 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 6 AERS Search Oxycodone Extended-Release Tablets Search limited to brand name: –OxyContin® 7300 reports retrieved Narrative search for terms: –crush, chew, inhale, dissolve, inject, and snort Search limited to brand name: –OxyContin® 7300 reports retrieved Narrative search for terms: –crush, chew, inhale, dissolve, inject, and snort

7 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 7 Narrative Search for Oxycodone Extended-Release Tablets Total number of reports evaluated380 Reports excluded –did not involve manipulation of OxyContin® 171 Reports further evaluated –to determine method of manipulation 209

8 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 8 OxyContin® Manipulation Reports Medication errors (n=22) –healthcare practitioners crushing tablets for ease of administration –labeling includes warnings against crushing or chewing Abuse (n=187) Medication errors (n=22) –healthcare practitioners crushing tablets for ease of administration –labeling includes warnings against crushing or chewing Abuse (n=187)

9 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 9 Methods of Manipulation OxyContin® Methods of manipulation (n=114) crush90 chew16 cut2 grind2 melt2 crack1 dissolve1 Methods of administration (n=95) inject69 snort26

10 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Manipulation of Oral Morphine Extended-Release Products

11 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 11 AERS Search Morphine Extended-Release Products Search limited to brand names: –Capsules: Avinza®, Kadian® –Tablets: MS Contin®, Oramorph® SR 2063 reports retrieved Narrative search for terms: –chew, crack, crush, cut, dissolve, grind, inhale, inject, melt, and snort. Duplicate reports grouped into cases Search limited to brand names: –Capsules: Avinza®, Kadian® –Tablets: MS Contin®, Oramorph® SR 2063 reports retrieved Narrative search for terms: –chew, crack, crush, cut, dissolve, grind, inhale, inject, melt, and snort. Duplicate reports grouped into cases

12 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 12 Narrative Search Morphine Extended-Release Products Total number of cases evaluated95 Cases excluded –did not involve manipulation of oral morphine extended-release products 73 Cases further evaluated –to determine method of manipulation 22

13 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 13 Morphine Extended-Release Product Manipulation Cases Medication errors (n=6) –crushing tablets for ease of administration –labeling includes warnings against crushing or chewing Abuse (n=16) Medication errors (n=6) –crushing tablets for ease of administration –labeling includes warnings against crushing or chewing Abuse (n=16)

14 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 14 Methods of Manipulation Morphine Extended-Release Products Methods of manipulation (n=18) crush11 chew3 boiling or heating2 dissolve2 Methods of administration (n=22) inject11 oral8 snort2 g-tube1

15 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 15 SummarySummary Manipulation associated with abuse –Manipulation is not completely representative of all abuse Injection - most prevalent method of administration reported Manipulation associated with abuse –Manipulation is not completely representative of all abuse Injection - most prevalent method of administration reported

16 Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 16 AcknowledgementsAcknowledgements LCDR Kristina Arnwine, Pharm. D CDR Melina N. Griffis, R.Ph. LCDR Cathy A. Miller, M.P.H., B.S.N. Division of Medication Error Prevention and Analysis Office of Surveillance and Epidemiology LCDR Kristina Arnwine, Pharm. D CDR Melina N. Griffis, R.Ph. LCDR Cathy A. Miller, M.P.H., B.S.N. Division of Medication Error Prevention and Analysis Office of Surveillance and Epidemiology

Download ppt "Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees November 13 & 14, 2008 Reported Manipulation of Oxycodone Extended-Release."

Similar presentations

The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.

The Vaccine Adverse Event Reporting System: A Tool for Safety and Surveillance Jane Woo, MD, MPH Vaccine Safety Branch Division of Epidemiology Office.
Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.

Postmarket Surveillance of Medical Device Adverse Events Hesha Jani Duggirala, PhD Epidemiology Branch Division of Postmarket Surveillance Office of Surveillance.
Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.

Importance of Vaccine Safety Decreases in disease risks and increased attention on vaccine risks Public confidence in vaccine safety is critical Low tolerance.
Julianne Gee, MPH Immunization Safety Office

Julianne Gee, MPH Immunization Safety Office
12-16-031 Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.

Safety Review for Plan B Daniel Davis, MD, MPH Division of Reproductive/Urologic Drugs.
Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.

Data Mining AERS FDA’s (Spontaneous) Adverse Event Reporting System Division of Drug Risk Evaluation Office of Drug Safety Carolyn McCloskey, M.D., M.P.H.
Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.

Anesthetic and Life Support Drugs, and Drug Safety and Risk Management Advisory Committees, November 13, 2008 Outpatient Drug Utilization Trends for Oxycodone.
Data Mining in VAERS to Enhance Vaccine Safety Monitoring at the FDA

Data Mining in VAERS to Enhance Vaccine Safety Monitoring at the FDA
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees May 5, 2008 Reported Manipulation of OxyContin Tablets LCDR Kristina.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees May 5, 2008 Reported Manipulation of OxyContin Tablets LCDR Kristina.
Monitoring Safety of Rotavirus Vaccines David Martin, MD, MPH CBER Office of Biostatistics and Epidemiology, FDA For presentation at the Vaccines and Related.

Monitoring Safety of Rotavirus Vaccines David Martin, MD, MPH CBER Office of Biostatistics and Epidemiology, FDA For presentation at the Vaccines and Related.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.

Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.

FDA’s MedWatch Program Outreach to Healthcare Professionals and the Public n Managing the Risks of Medical Product Use.
Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.

Anesthetic and Life Support Drugs and Drug Safety and Risk Management Advisory Committees, November 13 & 14, 2008 History of OxyContin: Labeling and Risk.
Adverse Event Reports on Automatic External Defibrillators from 1996 - 2003 Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.

Adverse Event Reports on Automatic External Defibrillators from Oscar H Tovar MD and Beverly Gallauresi RN, MPH Food and Drug Administration.
Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.

Prescription Drug Abuse Sharon Hertz, M.D. Medical Officer Division of Anesthetic, Critical Care and Addiction Drug Products Food and Drug Administration.
Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.

Vaccine Safety Epidemiology and Prevention of Vaccine- Preventable Diseases National Immunization Program Centers for Disease Control and Prevention Revised.
Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator.

Pediatric AC 6/9/041 Neonatal withdrawal syndrome with Serotonin Reuptake Inhibitors Office of Drug Safety Review Kathleen Phelan, R.Ph., Safety Evaluator.
Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.

Abuse Liability of Hydromorphone Extended Release Capsules Silvia N. Calderon, Ph.D. Controlled Substance Staff Center for Drug Evaluation and Research.
1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse.

1 National Estimates from the Drug Abuse Warning Network CAPT Kathy Poneleit United States Public Health Service Office of Applied Studies Substance Abuse.
Summary of Drug Abuse “Rates” in the United States: Focus on Morphine Catherine Dormitzer, PhD, MPH Division of Epidemiology Office of Surveillance and.

Summary of Drug Abuse “Rates” in the United States: Focus on Morphine Catherine Dormitzer, PhD, MPH Division of Epidemiology Office of Surveillance and.

Similar presentations

Ads by Google